This is an exploratory study in cancer biomarker research, hoping to identify cell-signaling using DNA, in patients with SCLC.
The purpose of this study is to evaluate a new test being developed by Tempus for patients with Non-Small Cell Lung Cancer (NSCLC). The goal of this new test is to predict the likelihood of a patient's cancer coming back after treatment, and to further explore changes in patient's tumors throughout treatment to see how they respond.
The purpose of this study is to determine if it is possible to identify biomarkers that tell us what type of response a person with metastatic breast cancer (MBC) will have to "antibody-drug conjugates" (ADCs).
The purpose of this study is to determine the safety of the addition of universal donor, expanded NK cells to gemcitabine/docetaxel for treatment of relapsed and refractory sarcomas.
The purpose of this study is to assess the efficacy as well as safety and tolerability of a new drug called padsevonil that will be given in one of 3 different doses in addition to your current epilepsy treatment that may consist of 1-3 antiepileptic drugs. The study also aims to see how safe padsevonil is compared to placebo and how well your body can tolerate it.
To initiate and evaluate a multilevel navigation intervention to promote lung cancer screening among Black/African Americans
Osteosarcoma is the most common primary bone malignancy of childhood and adolescence. Survival rates for patients with standard risk (localized, resectable primary tumors) and high-risk disease (presence of metastases, unresectable or primary pelvic tumors) are 70% and 20-30%, respectively, and have remained unchanged for several decades despite numerous attempts to augment standard therapies. Multi-targeted receptor tyrosine kinase inhibitors (MTKIs), such as cabozantinib, can target signaling pathways that are known to be altered in osteosarcoma. Several MTKIs including cabozantinib have recently shown clinical evidence of activity in prospective studies for both pediatric and adult patients with advanced osteosarcoma. Furthermore, feasibility of administering MTKIs in combination with cytotoxic chemotherapy has previously been shown in patients with AML, hepatocellular carcinoma, and soft tissue sarcomas. Osteosarcoma is the most common primary bone malignancy of childhood and adolescence. Survival rates for patients with standard risk (localized, resectable primary tumors) and high-risk disease (presence of metastases, unresectable or primary pelvic tumors) are 70% and 20-30%, respectively, and have remained unchanged for several decades
To determine in a randomized manner whether the addition of levocarnitine prophylaxis to asparaginase-containing regimens will decrease the incidence of conjugated hyperbilirubinemia (>3 mg/dL) during ALL induction therapy in adolescents and young adults (AYAs, age 15-39 years).
The DNA that we can test from a nasal swab, can help us determine a patient's lung cancer risk. For patients with new lung nodules found on CT scans, we are offering this nasal swab test and collecting data on how physicians use test results to help assess risk and determine treatment strategies.
This study is being done to answer the following question: Can we lower the chance of your bladder cancer growing or spreading by using one type of chemotherapy instilled in the bladder, Gemcitabine and Docetaxel, instead of the usual BCG therapy? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your bladder cancer. The usual approach is defined as care most people get for bladder cancer.